NCT06485557View on ClinicalTrials.gov

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 1, 2026

Conditions
Resectable Non-small Cell Lung Cancer
Interventions
DRUG

sintilimab plus platinum-based chemotherapy

The subjects in group A will receive 3 cycles of sintilimab plus platinum-based chemotherapy

DRUG

sintilimab plus platinum-based chemotherapy

The subjects in group B will receive 2 cycles of sintilimab plus platinum-based chemotherapy plus 1 cycle of sintilimab

DRUG

sintilimab plus platinum-based chemotherapy

The subjects in group C will receive 1 cycle of sintilimab plus platinum-based chemotherapy plus 2 cycles of sintilimab.

All Listed Sponsors
lead

Tang-Du Hospital

OTHER